{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:42:04Z","timestamp":1784860924081,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1564,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1093\/annonc\/mdv214","type":"journal-article","created":{"date-parts":[[2015,5,3]],"date-time":"2015-05-03T00:41:18Z","timestamp":1430613678000},"page":"1760-1765","source":"Crossref","is-referenced-by-count":43,"title":["High-dose clarithromycin is an active monotherapy for patients with relapsed\/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial"],"prefix":"10.1016","volume":"26","author":[{"given":"A.J.M.","family":"Ferreri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kiesewetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Govi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Scarf\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Donadoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv214_bb0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.critrevonc.2007.04.009","article-title":"Marginal-zone lymphoma","volume":"63","author":"Ferreri","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdv214_bb0015","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.semcancer.2013.09.004","article-title":"Marginal zone lymphomas and infectious agents","volume":"23","author":"Ferreri","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1093\/annonc\/mdv214_bb0020","first-page":"133","article-title":"Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production","volume":"25","author":"Aoki","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdv214_bb0025","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/47.6.867","article-title":"The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages","volume":"47","author":"Kurdowska","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1093\/annonc\/mdv214_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0009-9236(98)90030-3","article-title":"Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein","volume":"64","author":"Wakasugi","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1093\/annonc\/mdv214_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000007256","article-title":"Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer","volume":"46","author":"Hamada","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1093\/annonc\/mdv214_bb0040","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1440-1681.2000.03308.x","article-title":"Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo","volume":"27","author":"Wang","year":"2000","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1093\/annonc\/mdv214_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3835(98)00110-4","article-title":"Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic","volume":"131","author":"Yatsunami","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdv214_bb0050","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BiRD (Biaxin [clarithromycin]\/Revlimid [lenalidomide]\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma","volume":"111","author":"Niesvizky","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv214_bb0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/sonc.2003.50044","article-title":"Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone","volume":"30","author":"Coleman","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdv214_bb0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","article-title":"Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial","volume":"150","author":"Govi","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdv214_bb0065","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","author":"Ferreri","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv214_bb0070","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv214_bb0075","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gut.2005.083022","article-title":"Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas","volume":"55","author":"Raderer","year":"2006","journal-title":"Gut"},{"key":"10.1093\/annonc\/mdv214_bb0080","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1053\/gast.1999.0029900514b","article-title":"Regression of MALT lymphoma of the rectum after anti-H. pylori therapy in a patient negative for H. pylori","volume":"117","author":"Inoue","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdv214_bb0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-2002-23643","article-title":"The possible involvement of micro-organisms other than Helicobacter pylori in the development of rectal MALT lymphoma in H. pylori-negative patients","volume":"34","author":"Nakase","year":"2002","journal-title":"Endoscopy"},{"key":"10.1093\/annonc\/mdv214_bb0090","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00347-012-2724-7","article-title":"Clarithromycin therapy of a B cell MALT lymphoma","volume":"110","author":"Danilko","year":"2013","journal-title":"Ophthalmologe"},{"key":"10.1093\/annonc\/mdv214_bb0095","article-title":"Clarithromycin leading to complete remission in the first-line treatment of ocular adnexal mucosa-associated lymphoid tissue lymphoma","author":"Kiesewetter","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Suppl B","key":"10.1093\/annonc\/mdv214_bb0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/41.suppl_2.47","article-title":"Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin","volume":"41","author":"Scaglione","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1093\/annonc\/mdv214_bb0105","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv214_bb0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv214_bb0115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","article-title":"Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)","volume":"22","author":"Conconi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv214_bb0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdv214_bb0125","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/annonc\/mdp349","article-title":"Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"20","author":"Troch","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv214_bb0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdv214_bb0135","doi-asserted-by":"crossref","first-page":"e19510","DOI":"10.1200\/jco.2014.32.15_suppl.e19510","article-title":"An open-label randomized controlled phase II study of clarithromycin (CL) plus CVP in patients (pts) with previously untreated stage III\/IV indolent non Hodgkin lymphoma","volume":"32","author":"Saad","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv214_bb0140","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1002\/ajh.23733","article-title":"Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma","volume":"89","author":"Ghosh","year":"2014","journal-title":"Am J Hematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/8\/1760\/16699695\/mdv214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T19:38:59Z","timestamp":1717875539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0923753419318435"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv214","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}